|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,970 DKK | +0.79% |
|
-2.96% | -8.58% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Genmab A/S re-affirmed revenue guidance for the year 2024. For the year 2024, the company?s revenue guidance is unchanged and expected to be in the range of DKK 18.7 billion to DKK 20.5 billion.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.58% | 18.15B | |
| -2.58% | 103B | |
| +1.50% | 95.28B | |
| +1.46% | 22.15B | |
| -15.73% | 21.02B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.18% | 13.68B | |
| +33.45% | 12.17B | |
| -24.81% | 8.24B |
GENMAB A/S 
